SJEPD039_D.RNA-Seq
EPN · Posterior Fossa EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Posterior Fossa EPN
- cancer_type
- EPN
- subtype
- Posterior Fossa EPN
- age_years
- 5.96
- e1_e2
- E2
- umap1_2d
- -6.561203307
- umap2_2d
- -0.869747659
- umap1_3d
- 0.610264436
- umap2_3d
- 2.681689911
- umap3_3d
- 1.045480599
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.360
- COAGULATION+0.300
- XENOBIOTIC_METABOLISM+0.300
- ADIPOGENESIS+0.270
- BILE_ACID_METABOLISM+0.270
- OXIDATIVE_PHOSPHORYLATION+0.260
- PEROXISOME+0.260
- DNA_REPAIR+0.240
- FATTY_ACID_METABOLISM+0.240
- MYOGENESIS+0.230
Top 10 suppressed
- G2M_CHECKPOINT-0.530
- E2F_TARGETS-0.480
- MITOTIC_SPINDLE-0.400
- UV_RESPONSE_DN-0.310
- ANDROGEN_RESPONSE-0.290
- NOTCH_SIGNALING-0.230
- MTORC1_SIGNALING-0.220
- ALLOGRAFT_REJECTION-0.210
- PI3K_AKT_MTOR_SIGNALING-0.200
- HEDGEHOG_SIGNALING-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD001528_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.846 |
| 2 | SRR4296108 | — | cohortA1 | 0.804 |
| 3 | TCGA-LL-A9Q3-01A-11R-A41B-07 | — | B | 0.773 |
| 4 | SRR25043613 | — | — | 0.773 |
| 5 | SJEPD001524_R1.RNA-Seq | EPN | Posterior Fossa EPN | 0.772 |
| 6 | SRR1433600 | GTEX | — | 0.735 |
| 7 | SJEPD001527_R1.RNA-Seq | EPN | Posterior Fossa EPN | 0.729 |
| 8 | TCGA-55-A492-01A-11R-A24H-07 | — | cohortA2 | 0.726 |
| 9 | TCGA-OR-A5L3-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.719 |
| 10 | SJEPD011_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.717 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.360 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.300 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.270 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| PEROXISOME | 0.260 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| MYOGENESIS | 0.230 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.220 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.150 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.120 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.110 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.090 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.040 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.030 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.030 | Idelalisib | — uncovered |